药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tazarotene
Indenolol
The risk or severity of QTc prolongation can be increased when Indenolol is combined with Arsenic trioxide.
Tazarotene
Ivosidenib
The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Arsenic trioxide.
Tazarotene
Dexverapamil
The risk or severity of QTc prolongation can be increased when Dexverapamil is combined with Arsenic trioxide.
Tazarotene
Penfluridol
The risk or severity of QTc prolongation can be increased when Penfluridol is combined with Arsenic trioxide.
Tazarotene
Dexchlorpheniramine
The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Arsenic trioxide.
Tazarotene
Lorcainide
The risk or severity of QTc prolongation can be increased when Lorcainide is combined with Arsenic trioxide.
Tazarotene
Bunaftine
The risk or severity of QTc prolongation can be increased when Bunaftine is combined with Arsenic trioxide.
Tazarotene
Nizofenone
The risk or severity of QTc prolongation can be increased when Nizofenone is combined with Arsenic trioxide.
Tazarotene
Otilonium
The risk or severity of QTc prolongation can be increased when Otilonium is combined with Arsenic trioxide.
Tazarotene
Sultopride
The risk or severity of QTc prolongation can be increased when Sultopride is combined with Arsenic trioxide.
Tazarotene
Sitafloxacin
The risk or severity of QTc prolongation can be increased when Sitafloxacin is combined with Arsenic trioxide.
Tazarotene
Oxatomide
The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Arsenic trioxide.
Tazarotene
Abexinostat
The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Arsenic trioxide.
Tazarotene
Mizolastine
The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Arsenic trioxide.
Tazarotene
Ricolinostat
The risk or severity of QTc prolongation can be increased when Ricolinostat is combined with Arsenic trioxide.
Tazarotene
Simendan
The risk or severity of QTc prolongation can be increased when Simendan is combined with Arsenic trioxide.
Tazarotene
CUDC-101
The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Arsenic trioxide.
Tazarotene
Gilteritinib
The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Arsenic trioxide.
Tazarotene
Entinostat
The risk or severity of QTc prolongation can be increased when Entinostat is combined with Arsenic trioxide.
Tazarotene
Mocetinostat
The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Arsenic trioxide.